Eli Lilly and Co., Novo Nordisk A/S, and Sanofi SA are three key vendors highlighted in a new Technavio report
London, 03 September 2015 – Technavio has published a new report on the insulin market in Europe, which is expected to grow at a CAGR of more than 6% from 2015-2019.
Insulin market segmentation by type
Technavio’s report analyses the solutions and products offered by market vendors and presents a comprehensive breakdown in terms of market segmentation for different types of insulin, including fast-acting insulin, intermediate-acting insulin, and long-acting insulin.
The new report by Technavio discusses the initiatives taken by the EU government in promoting awareness programs for diabetes. The Seventh Framework Program (FP7) by the European Commission for the R&D of novel drugs focuses on the causes, prevention, and treatment of different types of diabetes, with special attention on juvenile diseases in childhood.
“The growing public awareness of diabetes and the available treatments is expected to increase the number of people opting for these treatments. Healthcare companies are organizing awareness camps and discussions to educate people about the condition,” says Faisal Ghaus, Vice President of Technavio.
Insulin: Market scope and calculation of market size
This report covers the present scenario and growth prospects for the insulin market in Europe from 2015-2019. To calculate the market size, we consider revenue generated from sales of insulin used in the treatment of diabetes.
Industry analysis includes:
Key Vendors:
- Eli Lilly and Co.
- Novo Nordisk A/S
- Sanofi SA
Market Growth Drivers:
- Increased Prevalence of Diabetes
- High Proportion of Elderly People
Market Challenges:
- Stringent Regulatory Environment
- Complexity of Insulin Production
Market Trends:
- Increased R&D for Novel Therapies
- Rise in Awareness Programs and Government Initiatives
View the insulin market in Europe report.
https://www.technavio.com/%3Cp%3E%3Cstrong%3E%3Ca%20href%3D%22http%3A//ww…
